CRISPR-Based System Identifies Important New Drug Targets in a Deadly Leukemia-Cold Spring Harbor Laboratory


Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered a way
to rein in an overactive protein that drives some aggressive leukemias. The renegade molecule,
MEF2C, belongs to a class of proteins that is notoriously difficult to manipulate with drugs. But
the new research suggests an opportunity to develop therapies against it.